Trial intelligence / Profile preview

Zoledronate to prevent bone loss in acute multiple sclerosis

ISRCTN87039596Phase 4Terminated

Sponsor
North Bristol NHS Trust
Start
Apr 2009
Modality
Small Molecules
01

Overview

Phase 4 trial of zoledronate in multiple sclerosis (MS) (2 arms), sponsored by North Bristol NHS Trust. Primary endpoint: Serum type I collagen C-telopeptides difference at day 7. Started Apr 2009; status: terminated.

02

Drugs

zoledronate
03

Conditions

multiple sclerosis (MS)

Beyond the preview

Go deeper on ISRCTN87039596.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ISRCTN87039596.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call